HALEOSLABS

HALEOS LABS financials

Market cap
₹442 Cr
Sector
Healthcare

What HALEOS LABS LIMITED does

The company manufactures Active Pharmaceutical Ingredients (APIs) and pharmaceutical intermediates for generic and innovator drug makers worldwide, operating since 1990 from a corporate office and manufacturing/research facilities in Hyderabad. Its majority-owned subsidiary, Mahi Drugs Private Limited, runs a separate API-intermediates plant at Parawada, Visakhapatnam. Products are exported to customers across markets including China, Indonesia, USA, Malaysia, Singapore, Spain and Brazil. The company was renamed from SMS Lifesciences India Limited to Haleos Labs Limited in 2025, with its underlying API/intermediates business unchanged.

Segments

  • APIs & Intermediates (standalone)
  • Intermediates of APIs (Mahi Drugs subsidiary)
Manufacturing facilities
2 API/intermediates plants — Unit 1 (Kazipally, Hyderabad, Telangana) and Mahi Drugs plant (Parawada, Visakhapatnam, Andhra Pradesh)
Unit 1 plant footprint
Plant area 47,581.62 Sq.M; built-up area 13,619.87 Sq.M; green belt 15,248 Sq.M
Mahi Drugs production lines
2 API lines & 4 intermediate blocks (213 KL); batch sizes 500 g to 1,000 kg
R&D facility
DSIR-approved R&D centre at Sanath Nagar, Hyderabad, staffed by a 70-member team
DMFs filed (FY25)
7 (across SMS Lifesciences & Mahi Drugs)
Export destinations
China, Indonesia, USA, Malaysia, Singapore, Spain, Brazil
Founded 1990Headquarters Hyderabad, Telangana Company website

Quarterly results

Q1 FY27: revenue down 14.2%, net profit down 37.2% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue79 83 85 79 78 −1%81 −3%63 −26%68 −14%
EBITDA12 13 6 11 11 −8%12 −12%6 +11%10 −11%
Net profit6 6 3 5 5 −17%5 −13%2 −17%3 −37%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Performance +25.9% 1Y

₹1.2k₹1.4k₹1.6kSept 25Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26

1Y: ₹1,161.5 on 10 Sept 2025 → ₹1,462.5. High ₹1,700 (11 May 2026), low ₹1,118.9 (10 Oct 2025).

Financials, as filed

Revenue grew 0.2% a year over 2 years, FY24 to FY26. Operating margin widened to 13.1%.

Year endingFY24FY25FY26
Revenue₹300 Cr₹333 Cr₹301 Cr
Operating profit₹34 Cr₹44 Cr₹39 Cr
Operating margin11.5%13.3%13.1%
Interest₹9 Cr₹8 Cr₹6 Cr
Depreciation₹10 Cr₹10 Cr₹11 Cr
Net profit₹13 Cr₹21 Cr₹18 Cr
Net margin4.4%6.4%5.9%
Cash from operations₹15 Cr₹28 Cr₹38 Cr
Free cash flow₹1 Cr₹14 Cr₹-11 Cr
ROCE11.0%14.0%11.0%
How to read this

From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.

Balance sheet

Year endingFY21FY22FY23FY24FY25FY26
Equity capital₹3 Cr₹3 Cr₹3 Cr₹3 Cr₹3 Cr₹3 Cr
Reserves₹123 Cr₹148 Cr₹161 Cr₹173 Cr₹203 Cr₹212 Cr
Borrowings₹45 Cr₹62 Cr₹87 Cr₹92 Cr₹70 Cr₹95 Cr
Other liabilities₹101 Cr₹99 Cr₹86 Cr₹80 Cr₹118 Cr₹94 Cr
Total liabilities₹272 Cr₹312 Cr₹337 Cr₹348 Cr₹394 Cr₹403 Cr
Fixed assets₹101 Cr₹99 Cr₹140 Cr₹138 Cr₹226 Cr₹190 Cr
Capital work in progress₹3 Cr₹21 Cr₹1 Cr₹6 Cr₹9 Cr₹1 Cr
Investments₹26 Cr₹23 Cr₹23 Cr₹23 Cr₹0 Cr₹23 Cr
Other assets₹142 Cr₹169 Cr₹174 Cr₹181 Cr₹159 Cr₹189 Cr
Total assets₹272 Cr₹312 Cr₹337 Cr₹348 Cr₹394 Cr₹403 Cr
How to read this

As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.

Who owns it

As disclosed at Jun 2026

Since Jun 2025, the public trimmed −0.98 pp while promoters added +0.70 pp. The shareholder count shrank 7% to 6,859.

Promoters
72.1%
DIIs
0.3%
Public
27.6%

Since Jun 2025

  • Public −0.98 pp
  • Promoters +0.70 pp
  • DIIs +0.31 pp

How it drifted, 12 quarters

Over this window the public fell from 29.7% to 27.6% — −2.1 pp.

Sep '23Dec '24Jun '26

Ownership split by quarter, oldest first. Sep '23: Promoters 70.3%, Public 29.7%.Dec '23: Promoters 70.7%, Public 29.3%.Mar '24: Promoters 71.2%, Public 28.8%.Jun '24: Promoters 71.4%, FIIs 0.0%, Public 28.6%.Sep '24: Promoters 71.4%, FIIs 0.0%, Public 28.6%.Dec '24: Promoters 71.4%, Public 28.6%.Mar '25: Promoters 71.4%, Public 28.6%.Jun '25: Promoters 71.4%, FIIs 0.0%, Public 28.6%.Sep '25: Promoters 71.4%, DIIs 0.0%, Public 28.6%.Dec '25: Promoters 71.8%, DIIs 0.3%, Public 27.9%.Mar '26: Promoters 72.1%, DIIs 0.3%, Public 27.6%.Jun '26: Promoters 72.1%, DIIs 0.3%, Public 27.6%.

Who was buying across the market this quarter →

Who is on the register

Named in the Jun 2026 filing

Every holder of HALEOS LABS LIMITED above SEBI's 1% disclosure line, and what changed since Mar 2026.

HolderStakeChange
Annapurna Talluri 24.56%unchanged
Tvvsn Murthy 15.88%unchanged
Venkata Praveen Talluri 9.06%unchanged
Ramesh Babu Potluri 7.94%unchanged
Sudeepthi Gopineedi 6.60%unchanged
Hima Bindu Potluri 2.76%unchanged
Trilok Potluri 2.58%unchanged
Vamsi Krishna Potluri 2.42%unchanged
Harita Projects Private - 2 1.76%unchanged
S Vijayakumar 1.11%unchanged
Potluri Infra Projects Llp 0.26%unchanged
Sukumari Koneru 0.02%unchanged

A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.

What the price assumes

Attractive

To justify its price of ₹1462, this stock must grow earnings at 19% every year for 7 years. Our analysis caps realistic growth at ~25%. At that growth it is worth ₹1953 — upside of 34%.

Growth the price implies
19.4% a year
for 7 years, fading to 4%
It has actually compounded at
25.1% a year
net profit, FY24–FY26 · EPS 25.1%
The gap
-0.1 pp
34% downside if it only repeats history
Price today ₹1,462.5 Value at the reference growth ₹1,953.02

Change the assumptions yourself →

Learn to analyse HALEOS LABS LIMITED

Guides on how to read this kind of business and the numbers that matter.